Announcements
- Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du cou
- Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- Assemblée Générale Mixte de Transgene du 15 mai 2024
- Transgene’s Combined General Meeting of May 15, 2024
- Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024
- Transgene provides business and financial update for Q1 2024
- Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024
- Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024
- Document d'enregistrement Universel 2023
- Availability of Transgene's 2023 Universal Registration Document
More ▼
Key statistics
As of last trade, Transgene SA (TGNA:FRA) traded at 1.28, 26.79% above the 52 week low of 1.01 set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.28 |
---|---|
High | 1.28 |
Low | 1.28 |
Bid | 1.28 |
Offer | 1.34 |
Previous close | 1.28 |
Average volume | 0.00 |
---|---|
Shares outstanding | 101.40m |
Free float | 35.83m |
P/E (TTM) | -- |
Market cap | 125.73m EUR |
EPS (TTM) | -0.2227 EUR |
Data delayed at least 15 minutes, as of Jun 07 2024 07:06 BST.
More ▼